红细胞分布宽度在肿瘤中的预后价值

doi:10.3760/cma.j.issn.1673-422X.2019.08.008

摘要/Abstract

摘要： 红细胞分布宽度（RDW）是既往用来诊断贫血的数字化指标，近年来的研究发现了其新的临床意义：除了急慢性肾脏疾病、慢性阻塞性肺病及心血管疾病外，RDW升高在实体瘤及血液肿瘤中也具有一定的预后意义，甚至可以作为某些肿瘤诊断的参考指标。尽管相关机制尚未明确，但作为廉价易获取的临床参数，RDW为肿瘤临床诊断及预后提供了新的方向。

关键词: 肿瘤, 预后, 红细胞分布宽度

Abstract: Red blood cell distribution width (RDW) is a conventional digital index for diagnosis of anemia, and recent studies have found its new clinical significance: high RDW is closely related to prognosis and diagnosis of both solid tumors and hematological tumors in addition to acute and chronic kidney disease, chronic obstructive pulmonary disease and cardiovascular disease. RDW, which is cheap and easily acquired, may offer a new direction for clinical diagnosis and prognosis of tumor though the relevant mechanism is unclear.

Key words: Neoplasms, Prognosis, Red blood cell distribution width

叶鉴南, 孙超, 李建勇, 周新. 红细胞分布宽度在肿瘤中的预后价值[J]. 国际肿瘤学杂志, 2019, 46(8): 485-488.

Ye Jiannan, Sun Chao, Li Jianyong, Zhou Xin. Prognostic value of red blood cell distribution width in tumors[J]. Journal of International Oncology, 2019, 46(8): 485-488.

参考文献

［1］ Arbel Y, Weitzman D, Raz R, et al. Red blood cell distribution width and the risk of cardiovascular morbidity and all-cause mortality. A population-based study［J］. Thromb Haemost, 2014, 111(2): 300-307. DOI: 10.1160/TH13-07-0567. ［2］ Solak Y, Yilmaz MI, Saglam M, et al. Red cell distribution width is independently related to endothelial dysfunction in patients with chronic kidney disease［J］. Am J Med Sci, 2014, 347(2): 118-124. DOI: 10.1097/MAJ.0b013e3182996a96. ［3］ Balta S, Aydogan M, Demirkol S, et al. Red cell distribution width: a novel and simple predictor of mortality in chronic obstructive pulmonary disease［J］. COPD, 2014, 11(4): 475-476. DOI: 10.3109/15412555.2013.813449. ［4］ Patel HH, Patel H, Higgins JM. Modulation of red blood cell population dynamics is a fundamental homeostatic response to disease［J］. Am J Hematol, 2015, 90(5): 422-428. DOI: 10.1002/ajh.23982. ［5］ Chrobk L, Zk P, Podzimek K, et al. Red cell distribution width (RDW) as a marker of disease activity in patients with hairy cell leukemia［J］. Acta Medica (Hradec Kralove), 1998, 41(1): 23-26. ［6］ Iriyama N, Hatta Y, Kobayashi S, et al. Higher red blood cell distribution width is an adverse prognostic factor in chronic-phase chronic myeloid leukemia patients treated with tyrosine kinase inhibitors［J］. Anticancer Res, 2015, 35(10): 5473-5478. ［7］ Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes［J］. N Engl J Med, 2014, 371(26): 2488-2498. DOI: 10.1056/NEJMoa1408617. ［8］ Podhorecka M, Halicka D, Szymczyk A, et al. Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia［J］. Oncotarget, 2016, 7(22): 32846-32853. DOI: 10.18632/oncotarget.9055. ［9］ Bulycheva E, Rauner M, Medyouf H, et al. Myelodysplasia is in the niche: novel concepts and emerging therapies［J］. Leukemia, 2015, 29(2): 259-268. DOI: 10.1038/leu.2014.325. ［10］ Muto Y, Nishiyama M, Nita A, et al. Essential role of FBXL5-mediated cellular iron homeostasis in maintenance of hematopoietic stem cells［J］. Nat Commun, 2017, 8: 16114. DOI: 10.1038/ncomms16114. ［11］ Raess PW, van de Geijn GJ, Njo TL, et al. Automated screening for myelodysplastic syndromes through analysis of complete blood count and cell population data parameters［J］. Am J Hematol, 2014, 89(4): 369-374. DOI: 10.1002/ajh.23643. ［12］ Baba Y, Saito B, Shimada S, et al. Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome［J］. Leuk Res, 2018, 67: 56-59. DOI: 10.1016/j.leukres.2018.02.004. ［13］ Periˇsa V, Zibar L, Sinˇci＇c-Petriˇcevi＇c J, et al. Red blood cell distribution width as a simple negative prognostic factor in patients with diffuse large B-cell lymphoma: a retrospective study［J］. Croat Med J, 2015, 56(4): 334-343. DOI: 10.3325/cmj.2015.56.334. ［14］ Zhou S, Fang F, Chen H, et al. Prognostic significance of the red blood cell distribution width in diffuse large B-cell lymphoma patients［J］. Oncotarget, 2017, 8(25): 40724-40731. DOI: 10.18632/oncotarget.16560. ［15］ Luo H, Quan X, Song XY, et al. Red blood cell distribution width as a predictor of survival in nasal-type, extranodal natural killer/T-cell lymphoma［J］. Oncotarget, 2017, 8(54): 92522-92535. DOI: 10.18632/oncotarget.21439. ［16］ Lee H, Kong SY, Sohn JY, et al. Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma.［J］. Biomed Res Int, 2014, 2014: 145619. DOI: 10.1155/2014/145619. ［17］ Meng S, Ma Z, Lu C, et al. Prognostic value of elevated red blood cell distribution width in Chinese patients with multiple myeloma［J］. Ann Clin Lab Sci, 2017, 47(3): 282-290. ［18］ Wang J, Xie X, Cheng F, et al. Evaluation of pretreatment red cell distribution width in patients with multiple myeloma［J］. Cancer Biomarker, 2017, 20(3): 267-272. DOI: 10.3233/CBM-170032. ［19］ Zhou D, Xu P, Peng M, et al. Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma［J］. Clin Chim Acta, 2018, 481: 34-41. DOI: 10.1016/j.cca.2018.02.009. ［20］ Zhang F, Chen Z, Wang P, et al. Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients［J］. Tumour Biol, 2016, 37(7): 9323-9331. DOI: 10.1007/s13277-015-4774-3. ［21］ Hirahara N, Matsubara T, Kawahara D, et al. Prognostic value of hematological parameters in patients undergoing esophagectomy for esophageal squamous cell carcinoma［J］. Int J Clin Oncol, 2016, 21(5): 909-919. DOI: 10.1007/s10147-016-0986-9. ［22］ Sun P, Zhang F, Cheng C, et al. The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China［J］. Oncotarget, 2016, 7(27): 42650-42660. DOI: 10.18632/oncotarget.9516. ［23］ Xie D, Marks R, Zhang M, et al. Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers［J］. J Thorac Oncol, 2015, 10(8): 1213-1220. DOI: 10.1097/JTO.0000000000000585. ［24］ Warwick R, Mediratta N, Shackcloth M, et al. Preoperative red cell distribution width in patients undergoing pulmonary resections for non-small-cell lung cancer［J］. Eur J Cardiothorac Surg, 2014, 45(1): 108-113. DOI: 10.1093/ejcts/ezt275. ［25］ Wang FM, Xu G, Zhang Y, et al. Red cell distribution width is associated with presence, stage, and grade in patients with renal cell carcinoma.［J］. Dis Markers, 2014, 2014: 860419. DOI: 10.1155/2014/860419. ［26］ Huang DP, Ma RM, Xiang YQ. Utility of red cell distribution width as a prognostic factor in young breast cancer patients［J］. Medicine (Baltimore), 2016, 95(17): e3430. DOI: 10.1097/MD.0000000000003430. ［27］ Wang C, Civan J, Lai Y, et al. Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables［J］. Cancer Causes Control, 2015, 26(1): 45-56. DOI: 10.1007/s10552-014-0481-4. ［28］ Seretis C, Seretis F, Lagoudianakis E, et al. Is red cell distribution width a novel biomarker of breast cancer activity? Data from a pilot study［J］. J Clin Med Res, 2013, 5(2): 121-126. DOI: 10.4021/jocmr1214w. ［29］ Lippi G, Targher G, Montagnana M, et al. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients［J］. Arch Pathol Lab Med, 2009, 133(4): 628-632. DOI: 10.1043/1543-2165-133.4.628. ［30］ Wu W, Ma D, Wang P, et al. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells［J］. FEBS J, 2016, 283(5): 834-849. DOI: 10.1111/febs.13633.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[14]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[15]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.